Introduction {#sec5}
============

Sex differences in schizophrenia have been described in almost all features of the illness, including incidence, prevalence, age at onset, symptomatology, course, and in the response to treatment, but only reliably established in age at onset and course \[[@ref1]\]. Sex-related differences in the illness course might be at least partially mediated by sex-related differences in cognitive functioning \[[@ref2]\]. Reduced cognitive performance is one of the core features of schizophrenia and an important predictor of outcome \[[@ref3]\]. Several studies have shown neurocognitive deficits already in patients with a so-called at-risk mental state (ARMS) for psychosis \[[@ref4]\]. Furthermore, it has been found that ARMS patients with later conversion to psychosis performed worse at baseline in tests measuring attention/vigilance, speed of processing, verbal and visual learning, and current and premorbid IQ compared with patients who did not convert \[[@ref4]\]. Consequently, several studies have shown that the prediction of transition to psychosis can be improved by including neurocognitive performance measures into multivariable risk prediction models \[[@ref4]\].

Cognitive performance is not only dependent on different stages of psychotic disorders, but also on sex. In healthy controls (HC), it is well established that women tend to perform better than men in tasks measuring verbal abilities (*d* = 0.24; for meta-analysis, see reference \[[@ref9]\]), whereas men tend to outperform women on visual--spatial tasks (*d* = 0.45; for meta-analysis, see \[[@ref9]\]) \[[@ref10]\]. Most studies indicate that these differences are also maintained in patients with schizophrenic psychoses (for reviews, see references \[[@ref1],[@ref2]\]). Specifically, many studies have shown that women diagnosed with schizophrenia have a better performance in verbal learning and memory \[[@ref1],[@ref13],[@ref14]\]. The female advantage in verbal domains has also been found in patients with first-episode psychosis (FEP), while men showed a better performance in tests of reaction time, visual memory, and executive functions \[[@ref1],[@ref10]\].

The impact of sex on cognitive functioning in ARMS has received considerable attention in the literature in recent years. A meta-regression analysis based on 19 studies assessing neuropsychological performance in 1,188 ARMS patients (women, *n* = 523; 44%) and 1,029 HC (women, *n* = 464; 45%) showed a trend-level significance effect of sex on cognitive performance, with females performing relatively better than males \[[@ref15]\]. Our own group investigated sex differences in cognitive functioning in 118 ARMS patients (women, *n* = 45; 38%), 88 FEP patients (women, *n* = 32; 36%), and 86 HC (women, *n* = 41; 47%) \[[@ref10]\]. Women performed better in the domain of verbal learning and memory whereas men showed a shorter reaction time during the working memory task across all groups. However, these differences did not withstand correction for multiple testing. Taken together, existing studies indicate that female patients with psychotic disorders or being at clinical high risk for psychosis do not perform better than males over and above what we see in HC.

To the best of our knowledge, the present study is the first to investigate sex differences in cognitive functioning in a large multinational sample of ARMS patients by using an extended neuropsychological battery and a healthy comparison group. The goal of the study was to elucidate whether sex differences in cognitive functioning differ between ARMS and HC subjects. Based on the evidence above and our own findings, we expected a better performance of women in the domain of verbal learning and memory irrespective of group.

Methods {#sec6}
=======

Setting and recruitment {#sec7}
-----------------------

The neuropsychological data analyzed in this study were collected within the EUropean Gene--Environment Interactions (EU-GEI) study, which aims to identify the interactive genetic, clinical, and environmental determinants of schizophrenia \[[@ref16]\]. EU-GEI is a naturalistic prospective multicenter study that consisted of a baseline and up to three follow-up time points (at 6 months, 12 months, and 24 months). Data were collected from May 1, 2010 to August 6, 2015. For the current analyses, only baseline data, that is, at intake into the study, were used.

ARMS participants were recruited from 11 Early Detection and Intervention Centers (London, Amsterdam, The Hague, Vienna, Basel, Cologne, Copenhagen, Paris, Barcelona, Melbourne, Saõ Paulo). They were referred to the EU-GEI study by primary health care services, mental health professionals, or themselves or their families.

Control participants were recruited by four of the above-mentioned centers: the Institute of Psychiatry, Psychology, and Neuroscience (IoPPN) in London, the Personal Assessment and Crisis Evaluation Clinic in Melbourne, and the Amsterdam Medical Center and Parnassia, The Hague. They were approached by telephone and through advertisements at educational institutes. In Melbourne, controls were additionally approached at community centers/noticeboards and advertised via online platforms. Controls were matched to the ARMS patients in terms of age, sex, migrant, and ethnic status. All participants were screened with an inclusion/exclusion checklist (see below).

The protocol of the EU-GEI study was approved by the institutional review boards of all study sites. EU-GEI was conducted in accordance with the Declaration of Helsinki. The Medical Ethics Committees of all participating sites approved the study protocol.

Inclusion and exclusion criteria {#sec8}
--------------------------------

Inclusion criteria for ARMS patients were: aged 14--45 (most of them were between 18 and 35 years); being at-risk for psychosis as defined by the comprehensive assessment of at-risk mental state (CAARMS) \[[@ref17]\]; adequate language skills corresponding to each center; and consent to study participation. The exclusion criteria were: prior experience of a psychotic episode of more than 1-week as determined by the CAARMS \[[@ref17]\] and Structural Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM Disorders (SCID)) \[[@ref18]\]; previous treatment with an antipsychotic for a psychotic episode; and IQ \< 60.

Inclusion criteria for controls were: aged 18--35; adequate language skills local to each center; no evidence of current or past psychosis (including treatment with antipsychotic medication). Exclusion criteria for controls were similar to those for ARMS participants. Additionally, controls were excluded if they met the criteria for an ARMS status as defined by the CAARMS \[[@ref17]\].

Detection procedure {#sec9}
-------------------

The CAARMS was used to identify ARMS patients \[[@ref17]\]. The CAARMS is a semi-structured interview that encompasses psychotic symptoms and a range of other psychopathological symptoms present during the psychosis prodrome. Individuals were classified as being in an ARMS for psychosis if they met at least one of the following risk criteria: (i) attenuated psychotic symptoms (psychotic symptoms subthreshold either in intensity or frequency); (ii) brief limited psychotic symptoms (recent episode of brief psychotic symptoms that spontaneously resolved within 1 week); or (iii) vulnerability group (a first-degree relative with a psychotic disorder or a diagnosis of a schizotypal personality disorder in combination with a significant drop in functioning). The full criteria can be found elsewhere \[[@ref17]\].

Assessment of sociodemographic and clinical characteristics {#sec10}
-----------------------------------------------------------

Sociodemographic characteristics (e.g. age, sex, ethnicity) were obtained using the modified Medical Research Council sociodemographic schedule \[[@ref19]\]. Current cannabis frequency was assessed with the modified version of the Cannabis Experience Questionnaire \[[@ref20]\]. Data on comorbid affective and anxiety disorders were assessed with the SCID \[[@ref18]\]. Psychiatric medication (i.e., use of antipsychotics, antidepressants, and sedatives) was obtained using a medical history questionnaire, designed by the EU-GEI group. The general level of functioning was assessed with the modified version of the Global Assessment of Functioning (GAF) scale \[[@ref21]\].

Classification and assessment of neuropsychology {#sec11}
------------------------------------------------

Neuropsychological performance of each participant was assessed by trained psychiatrists, psychologists, and research assistants. The neuropsychological tests covered the following seven domains: attention/vigilance, reasoning/problem solving, speed of processing, verbal learning, working memory, social cognition, and current IQ. Test scores were assigned to cognitive domains in accordance with Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) \[[@ref22]\]. Tests that are not part of the MCCB were assigned to domains according to their most commonly used function. The following measures were used to cover the cognitive domains of interest:Attention/vigilance: Digit Span Forward subtest of the Wechsler Adult Intelligence Scale-third edition (WAIS-III) \[[@ref23]\];Reasoning/problem solving: Beads Task \[[@ref24]\];Speed of processing: Digit Symbol Test of the WAIS-III and the Trail-Making Test parts A and B \[[@ref25]\];Verbal Learning: Rey Auditory Verbal Learning Test \[[@ref26]\];Working memory: Digit Span Backwards and Arithmetic subtests of the WAIS-III \[[@ref23]\];Social cognition: Degraded Affect Recognition Task \[[@ref27]\] and the Benton Facial Recognition Test \[[@ref28]\]; andCurrent IQ: Block Design total raw score, the information total raw score and the estimate of the total IQ of the shortened WAIS-III \[[@ref23],[@ref29]\].

Assessment of psychopathology {#sec12}
-----------------------------

The Brief Psychiatric Rating Scale expanded version (BPRS-E) \[[@ref30]\] was used to assess psychopathology. Sex differences were investigated using the BPRS total score and the following subscales: BPRS positive symptoms and BPRS negative symptoms \[[@ref31]\].

Statistical analyses {#sec13}
--------------------

All statistical analyses were performed using R \[[@ref32]\]. Because observations were nonindependent, that is, observations from the same center were more similar than observations from different centers, sex differences were analyzed using linear mixed effects models including sex and group (ARMS, HC) as a fixed effects factors and randomly varying intercepts per center to account for the clustering in the data. Linear mixed effects models were applied to evaluate the main effects of sex and group (ARMS, HC) as well as their interactions on cognitive functioning. Dependent variables were *z*-transformed before inclusion to models and sex was included as a binary variable with 0 and 1 describing men and women, respectively. Thus, the regression coefficient for sex described the standardized mean difference (SMD) of women compared with men. The results are presented with and without correction for multiple testing. We used the false discovery rate procedure to adjust *p*-values for multiple testing \[[@ref33]\].

Results {#sec14}
=======

Sample description {#sec15}
------------------

The sample of the present study consisted of 343 ARMS patients (185 men, 158 women) and 67 HC subjects (34 men, 33 women). Sociodemographic and clinical characteristics of our sample are presented in [Table 1](#tab1){ref-type="table"}. Cannabis use was more frequent in male ARMS patients than female ARMS patients (30.51% vs. 18.46% used cannabis at least a few times per year). With regard to comorbid affective and anxiety disorders, female ARMS patients showed more often a current anxiety disorder as well as posttraumatic stress disorders (PTSD) compared with male ARMS patients. There were no significant sex differences regarding any current affective disorder (i.e., current depressive, manic, or hypomanic episode and dysthymic disorder), neither for ARMS nor for HC. With regard to psychopathology, male ARMS patients showed significantly more severe BPRS "negative symptoms" (*p* = 0.006) than female ARMS patients. There were no sex differences in ARMS and HC with regard to age, years of education, current psychiatric medication, global functioning, BPRS "positive symptoms" and BPRS "total score."Table 1.Sociodemographic and clinical sample characteristicsARMSHCAllMenWomen*p* value*N*AllMenWomen*p* value*N*(*n* = 343)(*n* = 185)(*n* = 158)(*n* = 67)(*n* = 34)(*n* = 33)Age22.4 (4.91)22.7 (5.08)22.1 (4.70)0.21034322.9 (4.09)23.0 (4.09)22.7 (4.15)0.72067Ethnicity0.4813420.009[^\*\*^](#tab1fn2){ref-type="table-fn"}67 White245 (71.6%)136 (73.5%)109 (69.4%)42 (62.7%)23 (67.6%)19 (57.6%) Black34 (9.94%)18 (9.73%)16 (10.2%)10 (14.9%)8 (23.5%)2 (6.06%) Mixed28 (8.19%)16 (8.65%)12 (7.64%)6 (8.96%)0 (0.0%)6 (18.2%) Asian11 (3.22%)6 (3.24%)5 (3.18%)9 (13.4%)3 (8.82%)6 (18.2%) North African12 (3.51%)6 (3.24%)6 (3.82%)0 (0.0%)0 (0.0%)0 (0.0%) Other12 (3.51%)3 (1.62%)9 (5.73%)0 (0.0%)0 (0.0%)0 (0.0%)Years of education14.4 (3.07)14.4 (3.28)14.4 (2.83)0.98930216.1 (2.79)16.6 (2.97)15.6 (2.55)0.16965Cannabis current frequency0.029[^\*^](#tab1fn1){ref-type="table-fn"}3340.08167 None247 (74.0%)121 (68.4%)126 (80.3%)49 (73.1%)22 (64.7%)27 (81.8%) Only once or twice4 (1.20%)2 (1.13%)2 (1.27%)1 (1.49%)0 (0.0%)1 (3.03%) A few times each year17 (5.09%)7 (3.95%)10 (6.37%)4 (5.97%)4 (11.8%)0 (0.0%) A few times each month17 (5.09%)12 (6.78%)5 (3.18%)7 (10.4%)4 (11.8%)3 (9.09%) (More than) once a week11 (3.29%)9 (5.08%)2 (1.27%)3 (4.48%)1 (2.94%)2 (6.06%) Every day38 (11.4%)26 (14.7%)12 (7.64%)3 (4.48%)3 (8.82%)0 (0.0%)Antipsychotics currently30 (11.8%)15 (11.6%)15 (11.9%)1.0002550 (0.0%)0 (0.0%)0 (0.0%)56Antidepressants currently82 (32.2%)39 (30.2%)43 (34.1%)0.5952552 (3.57%)0 (0.0%)2 (7.14%)0.49156Sedatives currently15 (5.88%)7 (5.43%)8 (6.35%)0.9632551 (1.79%)0 (0.0%)1 (3.57%)1.00056Current affective disorder127 (37.0%)60 (32.4%)67 (42.4%)0.0733430 (0.0%)0 (0.0%)0 (0.0%)67Current anxiety disorder166 (48.4%)73 (39.5%)93 (58.9%)0.001[^\*\*^](#tab1fn2){ref-type="table-fn"}3435 (7.46%)2 (5.88%)3 (9.09%)0.67367Current OCD29 (9.70%)16 (10.1%)13 (9.29%)0.9752990 (0.0%)0 (0.0%)0 (0.0%)53Current PTSD34 (10.6%)11 (6.40%)23 (15.4%)0.015[^\*^](#tab1fn1){ref-type="table-fn"}3210 (0.0%)0 (0.0%)0 (0.0%)65GAF disability, impairment55.5 (12.3)55.8 (12.4)55.1 (12.1)0.58433185.0 (8.98)85.2 (8.15)84.7 (9.92)0.81966BPRS positive symptoms7.48 (3.17)7.67 (3.28)7.27 (3.03)0.2543233.17 (0.53)3.13 (0.43)3.21 (0.63)0.55059BPRS negative symptoms5.05 (2.40)5.38 (2.65)4.66 (2.02)0.006[^\*\*^](#tab1fn2){ref-type="table-fn"}3243.00 (0.00)3.00 (0.00)3.00 (0.00)0.32559BPRS total score43.6 (10.2)44.1 (10.6)43.0 (9.67)0.36132425.4 (2.61)25.3 (2.24)25.6 (3.01)0.61859[^1][^2][^3][^4]

Effects of sex and diagnostic group on cognitive functioning {#sec16}
------------------------------------------------------------

Means and standard deviations (*SD*) of the total group, ARMS, and HC are presented in [Table 2](#tab2){ref-type="table"}. [Table 3](#tab3){ref-type="table"} shows the results of the mixed effects models using neurocognitive performance as the continuous dependent variable and sex as well as group (ARMS, HC) as fixed effects factors. SMDs of the neuropsychological measures are additionally presented in [Figure 1](#fig1){ref-type="fig"}.Table 2.Means and standard deviations of neuropsychological test data in ARMS patients and HCTotal groupARMSHCAllMenWomenAllMenWomenAllMenWomen(*n* = 410)(*n* = 219)(*n* = 191)(*n* = 343)(*n* = 185)(*n* = 158)(*n* = 67)(*n* = 34)(*n* = 33)Attention WAIS-III Digit Span Forward9.69 (2.26)9.66 (2.19)9.73 (2.34)9.51 (2.20)9.50 (2.16)9.51 (2.24)10.7 (2.35)10.5 (2.18)11.0 (2.57)Current IQ Block Design total raw score43.8 (15.2)44.8 (15.2)42.7 (15.3)42.7 (15.5)43.8 (15.1)41.4 (15.8)49.3 (12.9)49.7 (14.8)48.9 (11.0) Estimate of total IQ101 (17.9)102 (18.7)100 (17.0)98.6 (16.8)99.9 (17.6)97.2 (15.9)113 (18.1)112 (20.5)113 (15.7) Information total raw score16.9 (6.56)17.5 (6.56)16.2 (6.51)16.3 (6.73)17.1 (6.71)15.5 (6.68)19.4 (4.98)19.4 (5.47)19.4 (4.52)Problem solving Beads task draws to decision6.62 (4.63)6.90 (5.06)6.31 (4.11)6.54 (4.70)6.74 (5.20)6.33 (4.09)7.02 (4.29)7.73 (4.21)6.22 (4.32)Social cognition BFR total correct22.3 (2.33)22.3 (2.24)22.3 (2.43)22.2 (2.32)22.3 (2.24)22.2 (2.42)22.6 (2.36)22.1 (2.31)23.1 (2.36) DFAR angry faces total correct10.2 (4.90)9.67 (4.90)10.7 (4.84)10.5 (4.71)9.99 (4.79)11.0 (4.58)8.61 (5.53)7.94 (5.23)9.30 (5.82) DFAR frightened faces total correct8.59 (4.25)8.17 (4.21)9.07 (4.26)8.80 (4.09)8.26 (4.09)9.43 (4.02)7.50 (4.89)7.68 (4.85)7.31 (5.01) DFAR happy faces total correct12.8 (5.08)12.5 (5.23)13.1 (4.89)13.1 (4.78)12.7 (5.07)13.5 (4.38)11.3 (6.23)11.4 (6.01)11.1 (6.54) DFAR neutral faces total correct11.4 (4.84)11.1 (4.95)11.6 (4.72)11.6 (4.57)11.3 (4.76)12.0 (4.31)10.2 (5.97)10.6 (5.92)9.81 (6.09)Speed of processing Digital Symbol Coding total raw score73.1 (16.1)70.2 (16.6)76.4 (15.0)71.7 (15.8)69.2 (16.6)74.5 (14.4)80.1 (15.9)75.2 (15.9)85.0 (14.6) TMT-A time to completion29.6 (12.3)30.7 (13.9)28.4 (10.1)30.2 (12.2)31.2 (13.6)29.1 (10.3)26.6 (12.8)28.1 (15.6)25.0 (8.62) TMT-B time to completion70.3 (29.4)74.6 (30.8)65.7 (27.2)73.2 (30.4)77.9 (31.6)68.0 (28.2)56.3 (18.8)58.0 (19.5)54.4 (18.2)Verbal learning RAVLT delayed recall correct10.7 (3.14)10.2 (3.31)11.4 (2.79)10.6 (3.05)10.0 (3.21)11.2 (2.72)11.4 (3.48)10.9 (3.76)12.0 (3.09) RAVLT trial 1 correct6.82 (2.02)6.58 (1.93)7.09 (2.09)6.69 (1.99)6.45 (1.86)6.98 (2.11)7.43 (2.04)7.25 (2.14)7.64 (1.93) RAVLT trials 1--5 correct52.2 (9.91)50.6 (9.68)54.0 (9.88)51.3 (9.98)49.9 (9.64)53.1 (10.1)56.3 (8.50)54.1 (9.20)58.7 (7.01)Working memory Arithmetic total raw score13.5 (4.76)14.1 (4.68)12.8 (4.76)13.1 (4.70)13.8 (4.64)12.3 (4.65)15.5 (4.58)15.9 (4.60)15.1 (4.60) WAIS-III Digit Span Backwards6.73 (2.27)6.74 (2.28)6.71 (2.27)6.60 (2.19)6.72 (2.30)6.46 (2.06)7.44 (2.58)6.87 (2.21)8.17 (2.87)[^5] Table 3.*p* values and coefficients of fixed effects of mixed effects modelsGroupSexGroup × sex*p* value*p* value corr[^a^](#tab3fn1){ref-type="table-fn"}Coef*p* value*p* value corr[^a^](#tab3fn1){ref-type="table-fn"}Coef*p* value*p* value corr[^a^](#tab3fn1){ref-type="table-fn"}CoefAttention WAIS-III Digit Span Forward\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}0.002[^\*\*^](#tab3fn3){ref-type="table-fn"}0.550.4410.5300.110.4670.7820.22Current IQ Block Design total raw score\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}0.590.3640.505−0.120.5610.7820.15 Estimate of total IQ\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}0.880.6580.697−0.060.3850.7820.22 Information total raw score\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}0.610.3290.493−0.130.2770.7740.29Problem solving Beads task draws to decision0.3310.4260.150.0980.252−0.230.6590.782−0.13Social cognition BFR total correct0.1430.1980.220.2010.3290.180.1240.7050.45 DFAR angry faces total correct0.4350.489−0.100.034[^\*^](#tab3fn2){ref-type="table-fn"}0.1510.250.6950.7820.09 DFAR frightened faces total correct0.4210.489−0.110.4090.5250.100.1120.705−0.40 DFAR happy faces total correct0.5310.563−0.080.5470.6150.070.3010.774−0.24 DFAR neutral faces total correct0.9220.922−0.010.9220.9220.010.2660.774−0.27Speed of processing Digital Symbol Coding total raw score\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}0.63\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}0.011[^\*^](#tab3fn2){ref-type="table-fn"}0.440.1570.7050.37 TMT-A time to completion0.017[^\*^](#tab3fn2){ref-type="table-fn"}0.028[^\*^](#tab3fn2){ref-type="table-fn"}−0.360.1620.291−0.200.5490.782−0.17 TMT-B time to completion\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}−0.650.1220.261−0.210.6410.7820.13Verbal learning RAVLT delayed recall correct0.026[^\*^](#tab3fn2){ref-type="table-fn"}0.040[^\*^](#tab3fn2){ref-type="table-fn"}0.330.003[^\*\*^](#tab3fn3){ref-type="table-fn"}0.019[^\*^](#tab3fn2){ref-type="table-fn"}0.410.9360.936−0.02 RAVLT trial 1 correct0.016[^\*^](#tab3fn2){ref-type="table-fn"}0.028[^\*^](#tab3fn2){ref-type="table-fn"}0.340.0690.2060.240.8740.926−0.04 RAVLT trials 1--5 correct\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}0.490.001[^\*\*^](#tab3fn3){ref-type="table-fn"}0.011[^\*^](#tab3fn2){ref-type="table-fn"}0.400.5930.7820.13Working memory Arithmetic total raw score\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}0.600.0640.206−0.240.5800.7820.14 WAIS-III Digit Span Backwards\<0.001[^\*\*\*^](#tab3fn4){ref-type="table-fn"}0.002[^\*\*^](#tab3fn3){ref-type="table-fn"}0.510.1300.2610.220.011[^\*^](#tab3fn2){ref-type="table-fn"}0.1970.75[^6][^7][^8][^9][^10] Figure 1.Cognitive performance of women compared with men in at-risk mental state for psychosis individuals and healthy controls. The dotted horizontal line at zero represents the performance of men. Differences are expressed in units of standard deviation and are significant if the 95% confidence interval (vertical line) does not overlap with zero. Variables with a minus sign were reversed so that positive scores always represent good performance. Abbreviations: RAVLT, Rey Auditory Verbal Learning Test; TMT, Trail Making Test; WAIS, Wechsler Adult Intelligence Scale.

In the combined sample of ARMS and HC, women recognized more angry faces in the "Degraded Faces Affect Recognition" social cognition task (*p* = 0.034, *b* = 0.25), performed better in the "Digital Symbol Coding" speed of processing task (*p* ≤ 0.001, *b* = 0.44) of the WAIS-III, and remembered more words in the "Rey Auditory Verbal Learning Test (RAVLT) delayed recall" (*p* = 0.003, *b* = 0.41) and "RAVLT trials 1 to 5" (*p* = 0.001, *b* = 0.40) than men. However, after correction for multiple testing, only the differences in "Digital Symbol Coding" and the RAVLT measures remained statistically significant.

Effects of diagnostic group are presented in [Table 3](#tab3){ref-type="table"}. ARMS patients performed significantly worse in all cognitive performance scores, except in all scores of the problem solving and social cognition tasks.

There was one statistically significant interaction between sex and group (ARMS, HC) on the "WAIS-III Digit Span Backwards" working memory task (*p* = 0.011), which was due to a significantly better performance of female HC compared with male HC (*p* \< 0.026, *b* = −0.59) and a nonsignificantly worse performance of female ARMS patients compared with male ARMS patients (*p* = 0.186, *b* = 0.16). However, this sex × group interaction was no longer significant after correction for multiple testing.

The results did not change, when age or frequent cannabis use (i.e., at least several times per week) were included as covariates.

Discussion {#sec17}
==========

To the best of our knowledge, this is the first study investigating sex-related neurocognitive performance differences in a multinational ARMS sample of this size, using a comprehensive neuropsychological battery and a healthy comparison group. In line with our hypotheses, women showed superior performance in the domain of verbal learning and memory independent of whether they were ARMS patients or HC. Furthermore, women outperformed men on measures of speed of processing (i.e., Digital Symbol Coding total raw score) and social cognition (i.e., Degraded Facial Affect Recognition Task (DFAR) angry faces total correct), whereas men outperformed women on a trend-wise level on a task of working memory (i.e., arithmetic total raw score). Additionally, our results show that ARMS patients displayed alterations in attention, current IQ, speed of processing, verbal learning, and working memory compared with HC. However, we will not discuss this aspect any further since it is not the focal point of the present study.

Finally, we found a sex × group interaction effect on working memory (i.e., WAIS-III Digit Span Backwards), which was due to a significantly better performance of female HC compared with male HC and a nonsignificantly better performance of male ARMS patients compared with female ARMS patients. However, only sex differences in the total group in speed of processing and verbal learning remained significant after correction for multiple testing.

With regard to verbal learning and memory, our finding that the female advantage is equally present in ARMS patients as in HC is in line with previous research \[[@ref1],[@ref15]\]. Furthermore, it corroborates the findings of an earlier study of our own group that reported no interaction effect between diagnostic group (i.e., ARMS, FEP, HC) and verbal learning and memory \[[@ref10]\].

Regarding processing speed, our finding that women perform better than men is also consistent with earlier findings from the general population \[[@ref34],[@ref35]\] and patients with schizophrenia \[[@ref36],[@ref37]\]. To the best of our knowledge, this is the first study examining sex differences in ARMS and healthy subjects by using well-established tests to evaluate processing speed (i.e., Trail Making Test, WAIS-III Digit Symbol subtest). A previous study has investigated sex-related cognitive performance differences in ARMS, FEP and HC but did not include tests specifically measuring processing speed \[[@ref10]\]. However, the authors found a shorter reaction time for men in the working memory task independent of diagnostic group. They explain the findings by a superior working memory performance rather than generally enhanced processing speed in men as no sex differences in reaction time during the Continuous Performance Test and the Go/No-Go subtest of the Test of Attentional Performance (TAP) were detected, while maintaining a comparable overall working memory performance level \[[@ref10]\].

A strength of our study is that we examined sex differences with well-established tests using the classification of the MATRICS panel \[[@ref22],[@ref38]\]. As the MCCB domains are well known in schizophrenia research, this may help future studies to compare sex-related cognitive performance differences in ARMS and schizophrenic patients. Furthermore, this is the first study to investigate sex differences in cognitive functioning in an ARMS sample of this size.

However, there are some limitations to the present study that need to be acknowledged. Our neuropsychological test battery was originally selected to identify genetic and environmental interactions in psychosis and not specifically to detect sex differences. Accordingly, the test battery did not include other sensitive tasks to detect sex differences such as visuo-spatial tasks. Additionally, the domain of visual learning in the MATRICS consensus battery was not covered. Furthermore, our control group was rather small in comparison to the ARMS group, which reduced the statistical power to detect interaction effects between sex and group. Finally, it is important to note that sex-related cognitive performance differences depend on a wide variety of conditions, for example, the severity of symptoms and especially the fluctuation of estrogen levels during the menstrual cycle in women (for review, see reference \[[@ref1]\]). There is evidence that high levels of estrogen at the mid-luteal point are associated with better verbal memory and diminished spatial ability \[[@ref39]\]. Thus, it is possible that some effects would have changed if we had measured women at a specific time point during their monthly cycle. Unfortunately, in our study no assessment of the time point during the monthly cycle was performed.

Taken together, our findings indicate that sex differences in cognitive functioning in ARMS patients are very similar to those seen in the general population and in schizophrenia patients.
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